Annual report pursuant to section 13 and 15(d)

Document and Entity Information

Document and Entity Information (USD $)
12 Months Ended
Dec. 31, 2011
Jun. 29, 2012
Jun. 30, 2011
Document Information [Line Items]      
Document Type 10-K    
Amendment Flag true    
AmendmentDescription On May 14, 2012, MusclePharm Corporation's (the "Company") independent registered public accounting firm and the Company's board of directors (the "Board") determined, after consultation with Company management that the Company's audited financial statements for the period ended December 31, 2011 and December 31, 2010, filed in an annual report on Form 10-K with the Securities and Exchange Commission (the "Commission") on April 16, 2012 and April 1, 2011, respectively, contained certain material misstatements. Our financial statements contained in this amended annual report on Form 10-K/A restate a previous error in accounting for the Company's calculation of net sales and presentation of general and administrative expenses. The Company has determined that advertising related credits that were granted to customers fell within the guidance of ASC No. 605-50-55 ("Revenue Recognition" - Customer Payments and Incentives - Implementation Guidance and Illustrations). The foregoing guidance indicates that, absent evidence of benefit to the vendor, appropriate U.S. GAAP treatment requires netting these types of payments against revenues and not expensing as advertising expense. The Company also noted other credits and discounts that, upon further review, had been previously classified as advertising expense as a component of general and administrative expense that require a reallocation of presentation as amounts to be netted against gross revenues. Additionally, for the year ended December 31, 2011, the Company reclassified certain items classified as samples originally included as an advertising expense to cost of sales. There were no such reclassifications for 2010. The Company previously deducted certain credits and promotions as general and administrative expenses. After a thorough analysis and review as noted above, the Company has determined to net any credits and promotions directly against gross sales instead of classifying the same amounts as an advertising expense. Because this accounting change is a reclassification of expenses in the Company's Consolidated Statements of Operations, the Company's net loss will not be affected by the restatement, nor does the restatement affect the net loss amounts reported in its unaudited quarterly financial statements during 2011 or audited Consolidated Balance Sheets at December 31, 2011 and December 31, 2010 or Consolidated Statement of Equity at December 31, 2011 and December 31, 2010 or Consolidated Statements of Cash Flows for the year ended December 31, 2011 and December 31, 2010.    
Document Period End Date Dec. 31, 2011    
Document Fiscal Year Focus 2011    
Document Fiscal Period Focus FY    
Trading Symbol MSLP    
Entity Registrant Name MUSCLEPHARM CORP    
Entity Central Index Key 0001415684    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Smaller Reporting Company    
Entity Common Stock, Shares Outstanding   1,399,074,207  
Entity Public Float     $ 5,637,180